Intravenous Ferric Carboxymaltose
Treatment for Iron Deficiency Anemia
Typical Dosage: Up to 1500 mg total in 1-2 infusions
Effectiveness
90%
Safety Score
68%
Clinical Trials
100
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Up to 1500 mg total in 1-2 infusions
Time to Effect
2-4 weeks
Treatment Duration
1-2 weeks initially, then as needed
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$1,600
Side Effect Mgmt:$100
Total Annual:$3,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$3,765
Cost per Remission
$4,129
Comparison vs Oral Ferrous Sulfate
Cost Difference
+$2,730/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Risk Assessment
Requires Monitoring
YesNeeds lab work/checkups
Intravenous Ferric Carboxymaltose Outcomes
for Iron Deficiency Anemia
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+77.5%
Common Side Effects
Hypophosphatemia (often asymptomatic)
+30%
Headache
+4%
Nausea
+3%
Dizziness
+2%
Injection site reactions
+1%
Hypersensitivity/Anaphylaxis
+0.1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Intravenous Ferric Carboxymaltose in Iron Deficiency Anemia
Impact of Intravenous Iron on Musculoskeletal Function in Older Adults
NCT05708170NOT YET RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Started: Jan 1, 2023
Completed Clinical Trials
14 completed trials for Intravenous Ferric Carboxymaltose in Iron Deficiency Anemia
Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)
NCT02232906COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Mar 1, 2011
A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia
NCT03399084COMPLETEDPHASE1
71 participants
INTERVENTIONAL
Miami, United States
Started: Nov 29, 2017
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
NCT06080555COMPLETEDPHASE1
84 participants
INTERVENTIONAL
Beijing, China +3 more
Started: Oct 9, 2023
Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
NCT01101399COMPLETEDPHASE3
19 participants
INTERVENTIONAL
Hamburg, Germany +1 more
Started: May 1, 2010
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
NCT03238911COMPLETEDPHASE3
123 participants
INTERVENTIONAL
Los Angeles, United States +15 more
Started: Oct 24, 2017
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
NCT03237065COMPLETEDPHASE3
122 participants
INTERVENTIONAL
Muscle Shoals, United States +14 more
Started: Oct 30, 2017
Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044
NCT04269707COMPLETEDPHASE3
7 participants
INTERVENTIONAL
Miami, United States +1 more
Started: Nov 19, 2019
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
NCT03957057COMPLETEDPHASE3
300 participants
INTERVENTIONAL
Ljubljana, Slovenia
Started: Sep 10, 2020
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
NCT03523117COMPLETEDPHASE3
79 participants
INTERVENTIONAL
Little Rock, United States +15 more
Started: Jan 31, 2019
Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON)
NCT04976179COMPLETEDPHASE3
1.06K participants
INTERVENTIONAL
Gwarzo, Nigeria +10 more
Started: Aug 9, 2021
Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
NCT03817957COMPLETEDPHASE3
187 participants
INTERVENTIONAL
Frankfurt, Germany
Started: Sep 18, 2018
A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA
NCT02410213COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Bydgoszcz, Poland +9 more
Started: Feb 19, 2015
Intravenous Iron in Adults With Cystic Fibrosis
NCT03632525COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Oxford, United Kingdom
Started: Feb 22, 2019
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
NCT01922479COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Singapore, Singapore +1 more
Started: Sep 1, 2013
Showing 20 of 103 total trials